Insmed Inc. (INSM) intrinsic value & 10-year financials
Insmed Inc. (INSM) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 80.2% a year to $606.4M, with an average return on invested capital of -310.9%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $96.27
- Market cap
- $19.2B
- Revenue (FY2025)
- $606.4M
- Revenue growth (10-yr CAGR)
- 80.2%
- ROIC (10-yr avg)
- -310.9%
- Free cash flow (FY2025)
- -$967.6M
INSM 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $606.4M | -$1.3B | -$6.42 | -$967.6M | -205.6% | -149.4% |
| FY2024 | $363.7M | -$913.8M | -$5.57 | -$705.8M | -241.5% | -141.0% |
| FY2023 | $305.2M | -$749.6M | -$5.34 | -$549.5M | -232.5% | -252.2% |
| FY2022 | $245.4M | -$481.5M | -$3.91 | -$410.3M | -186.4% | -190.8% |
| FY2021 | $188.5M | -$434.7M | -$3.88 | -$370.6M | -199.0% | -173.3% |
| FY2020 | $164.4M | -$294.1M | -$3.01 | -$225.6M | -161.3% | -180.2% |
| FY2019 | $136.5M | -$254.3M | -$3.01 | -$292.9M | -172.4% | -249.2% |
| FY2018 | $9.8M | -$324.3M | — | -$271.1M | -3124.9% | -942.6% |
| FY2017 | $0 | -$192.6M | — | -$162.6M | — | -459.3% |
| FY2016 | $0 | -$176.3M | — | -$150.9M | — | -371.4% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
INSMED Inc revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
INSMED Inc has historically struggled to out-earn its cost of capital, averaging just -31.9% ROIC.
Over the decade, INSMED Inc shows that the company has leveraged its balance sheet to sustain operations.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, INSMED Inc is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-213.24 per share.